Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat and FYVE domain containing 1 (ANKFY1) is a cytoplasmic protein characterized by a coiled-coil structure, a BTB/POZ domain at the N-terminus, multiple ankyrin repeats, and a FYVE-finger domain at the C-terminus[1][3][5]. As a Rab5 effector binding phosphatidylinositol 3-phosphate (PI(3)P) through its FYVE domain, ANKFY1 localizes to early endosomes and is essential for their formation and function[4]. It regulates intracellular trafficking and receptor trafficking, as demonstrated in endothelial cells where its depletion reduces surface expression of VEGF receptor 2, impairing downstream signaling important for cell proliferation and migration[1]. In neurons, particularly cerebellar Purkinje cells, ANKFY1 is necessary for cell maintenance, and its loss in mice leads to Purkinje cell degeneration and motor dysfunction, suggesting involvement in neurodegenerative processes[2]. Alternative splicing generates multiple transcript variants. Currently, ANKFY1 is not recognized as a direct drug target or therapeutic receptor, but its roles in cell trafficking and neurodegeneration continue to be areas of study[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat and FYVE domain containing 1 (ANKFY1).